We have assessed the overall level of tumor-infiltrating leukocytes (CD45+) and the level of “exhausted” CD8+ T cells expressing PD-1 inhibitory receptors as well as activation marker CD69 within the TME following applied treatment. The gene discussed is CD8A; the disease is neoplasm.